ClinicalTrials.gg

Program

veverimer

Also written as “TRC101” and “Veverimer”.

Its studies are mostly in Acidosis, led by 2 companies.

Furthest: phase 3, since Oct 11, 20175 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tricida40 open or runningphase 3since Oct 11, 2017Jun 14, 2016none ahead
Renibus Therapeutics11 open or runningphase 3since Nov 25, 2025Nov 25, 2025Jun 2027phase 3 · NCT07355062

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 14, 2016First study: phase 2 study in AcidosisNew to TricidaTricida · NCT02809183 · 135 enrolled · Bulgaria, Georgia
  2. Oct 11, 2017Phase 3 study in AcidosisTricida · NCT03317444 · 217 enrolled · United States, Bulgaria, Croatia and more
  3. Dec 28, 2017Phase 3 study in AcidosisTricida · NCT03390842 · 196 enrolled · United States, Bulgaria, Georgia and more
  4. Oct 11, 2018Phase 3 study in AcidosisTricida · NCT03710291 · 1,480 enrolled · United States, Albania, Argentina and more
  5. Nov 25, 2025Renibus Therapeutics's first study: phase 3 study in AcidosisNew to Renibus TherapeuticsRenibus Therapeutics · NCT07355062 · 150 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 3 study in AcidosisRenibus Therapeutics · NCT07355062

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07355062Acidosis · United States3RecruitingRenibus TherapeuticsJun 2027150
NCT03710291Acidosis · United States, Albania, Argentina and more3TerminatedTricidaAug 23, 20221,480
NCT03390842Acidosis · United States, Bulgaria, Georgia and more3CompletedTricidaFeb 22, 2019196
NCT03317444Acidosis · United States, Bulgaria, Croatia and more3CompletedTricidaMay 4, 2018217
NCT02809183Acidosis · Bulgaria, Georgia2CompletedTricidaNov 2016135

How it is read

Names in the registry

  • “TRC101”, 4 entries
  • “Veverimer”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.